Biotechnology News and Research

RSS

Affymetrix to acquire eBioscience

Affymetrix, Inc., and eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics, today announced they have amended their existing definitive agreement dated November 29, 2011 under which Affymetrix will acquire eBioscience.

4 May 2012

Integral Molecular receives U.S. patent for methodology that generates Lipoparticles

Integral Molecular, a leader in membrane protein reagents and services, announces the issuance of a key patent protecting its methodology for generating Lipoparticles, which provide highly-concentrated membrane proteins in their native conformation for antibody and drug discovery applications focused on membrane protein targets such as G protein-coupled receptors (GPCRs), ion channels, and transporters.

4 May 2012

Non-invasive imaging technique measures specific brain chemical changes

Alzheimer's disease (AD) is a major neurodegenerative disorder that affects millions of people worldwide. New and accurate techniques for early diagnosis are critical. Pravat K. Mandal, PhD, and his colleagues have developed a completely non-invasive brain imaging technique to measure specific brain chemical changes. This provides a signature of the early stages of AD from the hippocampal region of the brain.

3 May 2012

Johnson & Johnson announces acquisition of Bioseal

Johnson & Johnson (China) Investment Ltd. today announced it has acquired Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery.

3 May 2012

SC formulation of Genentech’s ACTEMRA shows promise against RA

Genentech, a member of the Roche Group, today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks.

3 May 2012

Flu paper publication amidst threats of bioterrorism raises need for better rules of censorship

According to the editor of the scientific journal Nature, Dr Philip Campbell current procedures to assess and censor medical research potentially of use to terrorists need to be improved. He was speaking about the recent controversy regarding the bird flu virus H5N1 study. The study was initially stopped from publication fearing risk of bioterrorism. He was speaking to BBC News.

2 May 2012

Levetiracetam to be tested for seizure management in malaria endemic regions

Michigan State University researchers, with the help of a groundbreaking medical device, are starting a clinical trial in Africa they hope will provide relief for the hundreds of thousands of children who survive cerebral malaria but are left stricken with epilepsy or other neurologic disorders.

2 May 2012

ImmuVen awarded $1.68M NIH Phase II SBIR grant to develop IMV0123

ImmuVen was awarded a Phase II Small Business Innovation Research (SBIR) grant totaling $1.68 million from the National Institute for Allergy and Infectious Disease (NIH) for continuing development of its therapeutic pipeline (IMV0123) against superantigens produced by methicillin-sensitive and methicillin-resistant Staphylococcal aureus.

2 May 2012

Lower rate of reintubation observed in infants receiving SURFAXIN

Discovery Laboratories, Inc. today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with SURFAXIN, when compared with infants treated with Curosurf® and Survanta®, the current global market leading surfactants, also resulted in a potential hospital cost savings of $160,000 to $252,000 per 100 infants.

2 May 2012

Lenalidomide and SNS01-T combination effective against multiple myeloma

Senesco Technologies, Inc. announced today that a high level of tumor eradication in a mouse model of human multiple myeloma was achieved with a combination of SNS01-T and lenalidomide.

2 May 2012

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.

2 May 2012

Ultragenyx reports results from UX001 Phase 1 study on HIBM

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration

2 May 2012

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

BioMed Realty first quarter total revenues increase 14.1% to $120.0M

BioMed Realty Trust, Inc., a real estate investment trust focused on Providing Real Estate to the Life Science Industry, today announced financial results for the first quarter ended March 31, 2012.

2 May 2012

Lixte submits IND with FDA to conduct LB-100 Phase I trial for cancer

John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc., announced the submission of an IND application to the Food and Drug Administration to conduct a Phase I trial of its lead, anti-cancer compound, LB-100.

2 May 2012

Kadimastem, Merck Serono enter agreement for MS drug-screening platform

Kadimastem, an Israeli Biotechnology company that develops human pluripotent stem cell-related products, today announced the signing of a five year framework agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

30 Apr 2012

Teva, Mylan settle patent infringement litigation for Nuvigil

Teva Pharmaceutical Industries Ltd., one of the world's largest producers of pharmaceuticals, announces that it has settled patent infringement litigation regarding U.S. Patent Number 7,132,570 (the "'570 patent") with respect to Mylan Inc.'s ANDA for Teva's wakefulness product NUVIGIL (armodafinil) tablets.

30 Apr 2012

Tolero granted exclusive global rights to commercialize MannKind's novel BTK compounds

Tolero Pharmaceuticals and MannKind Corporation today announced a license agreement granting Tolero exclusive worldwide rights to develop and commercialize compounds from MannKind's novel BTK (Bruton's tyrosine kinase) program, which are currently being developed for the treatment of hematological malignancies and inflammatory diseases.

30 Apr 2012

Mirror-microRNAs control multiple aspects of brain function

Our genes control many aspects of who we are - from the colour of our hair to our vulnerability to certain diseases - but how are the genes, and consequently the proteins they make themselves controlled? Researchers have discovered a new group of molecules which control some of the fundamental processes behind memory function and may hold the key to developing new therapies for treating neurodegenerative diseases.

30 Apr 2012

UAB researcher wins HudsonAlpha Prize for work on sickle cell and related blood disorders

Tim Townes, Ph.D., University of Alabama at Birmingham, was awarded the HudsonAlpha Prize for his work on sickle cell and related blood disorders. The $20,000 monetary award acknowledges exceptional talent, dedication and discovery by Alabama's best and brightest researchers.

30 Apr 2012